前颅窝及左筛窦动脉骨囊肿术后复发放射治疗1例报道并文献复习

74 蔡林波．等．前颅窝及左筛窦动脉骨囊肿术后复发放射治疗 1例报道并文献复习 [3] 【4】 [5】 【6】 【7] bone cyst of the sphenoid with orbital involvement lJ1． Br J Ophthalmol，1990，74：505—508． Pate1 PJ，Demos TC，Lomasney LM， et a1．Your diagnosis? Aneurysmal bone cyst [J】． Orthopedic， 2005，28：507． 牟仁琪，唐小峰，周承涛，等．动脉瘤样骨囊肿的鉴别 及诊断 (附21例)[J]．实用放射学杂志，2006，22 (11)：1378—1379． 常 恒，王 检，袁明远，等．动脉瘤样骨囊肿的影像 学诊断『J]．临床放射学杂志，2003，22(3)：210—212． 刘晓红，印建国，李传彪，等．鼻窦动脉瘤样骨囊肿的 临床及影像．诊断【J】．罕少疾病杂志，2006，13(1)：1-3． Miszczyk L，Wydmanski J，Spindel J．Efficacy of 【8】 【9】 [10】 radiotherapy for giant cell tumor of bone：given either postoperatively or as sole treatment【JJ．Int J Radiat Oncol BioI Phys，2001，49：1239—1242． Feigenberg SJ，Marcus RB Jr，Zlotecki RA，et a1． Radiation therapy for giant cell tumors of bone【J】．Clin O~hop Relat Res，2003，41 1：207—216． Feigenberg SJ，Marcus RB Jr．，Zlotecki RA，et a1． Megavohage radiotherapy for aneurismal bone cysts[J]．Int J Radiat Oncol Biol Phys，2001，49：1243—1247． 李 红．崔祥，刘秀萍，等．动脉瘤样骨囊肿的放射治 Of(附 19例报告)【J]．现代肿瘤医学，2004，12(2)：153一 】54． Phase I Clinical Trials in 93 Patients with Brain Metastases：The M ．D．Anderson Cancer Center Experience． Clin Cancer Res．2011 Mar 17．[Epub ahead ofprint] Tsimberidou AM，Letourneau K，Wen s，Wheler JJ,Hong DS，NaingA，Iskander NG， Uehara C Kurzrock R． Investigational Cancer Therapeutics，UT MD A nderson Cancer Center． PURPOSE：Patients with brain metastases are often excluded from clinical trials，but it is unclear if they pose an enhanced risk．EXPERIMENTAL DESIGN：We reviewed the records of 1，181 consecutive patients with and without brain metastases treated in the Phase I Clinical Trials Program． RESULTS：Ninety—three patients had brain metastases at the time of referra1．Their median age was 54 years；median follow—up，8 months．Th e rates of stable disease≥ 4 months／partial／complete response in patients with and without brain metastases were 17％and 27％，respectively =O．03)． Ahhough the median survival for patients with brain metastases was shorter than for that of patients without brain metastases(7．5 vs．10．3 months；P= 0．002)．in multivariate analysis the presence of brain metastases was not an independent factor predicting surviva1．There was no difference in time—to— treatment failure(1．74 vs．1．84 months，respectively；P=O．61)or in Grade 3-4 toxicity(including neurologic)between patients with and without brain metastases f12％vs．10％．P=0．77)．CONCLUSIONS：The rates of survival and response of patients with brain metastases were lower than those for other patients in the Phase I setting，but the presence of brain metastases was not an independent prognostic factor predicting survival，indicating that other covariates that co—exist with brain metastases were more significan t．Time—to—treatment failure for patients with brain metastases was not decreased，nor was the incidence of serious side effects (including neurologic toxicity)increased，suggesting that these patients should be eligible for early clinical trials． PMID：21415223【PubMed—as supplied by publisher]